Modality
Degrader
MOA
PRMT5i
Target
TIGIT
Pathway
PI3K/AKT
Ewing SarcomaEndometrial CaSchizophrenia
Development Pipeline
Preclinical
Oct 2021
PreclinicalCurrent
NCT03718299
752 pts·Ewing Sarcoma
2021-10→TBD·Completed
752 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-09-186mo awayEnrollment Complete· Schizophrenia
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Complet…
Catalysts
Enrollment Complete
2026-09-18 · 6mo away
Schizophrenia
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03718299 | Preclinical | Ewing Sarcoma | Completed | 752 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |